Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Prescient Therapeutics, Ltd.
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
City of Hope Medical Center
March Biosciences Inc
Institute of Hematology & Blood Diseases Hospital, China
Autolus Limited
Institute of Hematology & Blood Diseases Hospital, China
The Lymphoma Academic Research Organisation
The Lymphoma Academic Research Organisation
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Wake Forest University Health Sciences
Fondazione Italiana Linfomi - ETS
Yale University
The First Affiliated Hospital of Xiamen University
BeiGene
Emergent BioSolutions
M.D. Anderson Cancer Center
City of Hope Medical Center
Northwestern University
GWT-TUD GmbH
University of Kansas Medical Center
Dana-Farber Cancer Institute
Ruijin Hospital
Keimyung University Dongsan Medical Center
miRagen Therapeutics, Inc.
Brown University
National Institutes of Health Clinical Center (CC)
The First Affiliated Hospital of Soochow University
The Lymphoma Academic Research Organisation
Stanford University
miRagen Therapeutics, Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
Shandong Provincial Hospital
Celgene
Fred Hutchinson Cancer Center
Acrotech Biopharma Inc.